Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

被引：3

作者：

Sanchez-Castro, Judit ^{[1
]}

Marco-Betes, Victor ^{[1
]}

Gomez-Arbones, Xavier ^{[1
,2
]}

Garcia-Cerecedo, Tomas ^{[1
]}

Lopez, Ricard ^{[1
]}

Talavera, Elisabeth ^{[1
]}

Fernandez-Ruiz, Sara ^{[3
]}

Adema, Vera ^{[3
]}

Marugan, Isabel ^{[4
]}

Luno, Elisa ^{[5
]}

Sanzo, Carmen ^{[5
]}

Vallespi, Teresa ^{[6
]}

Arenillas, Leonor ^{[7
]}

Marco-Buades, Josefa ^{[8
]}

Batlle, Ana ^{[9
]}

Buno, Ismael ^{[10
]}

Luisa Martin-Ramos, Maria ^{[11
]}

Blazquez-Rios, Beatriz ^{[12
]}

Collado-Nieto, Rosa ^{[13
]}

Teresa Vargas, Ma ^{[14
]}

Gonzalez-Martinez, Teresa ^{[15
]}

Sanz, Guillermo ^{[16
]}

Sole, Francesc ^{[3
]}

机构：

[1] Hosp Arnau Vilanova, Lleida, Spain

[2] Univ Lleida, Lleida, Spain

[3] Inst Recerca Leucemia Josep Carreras IJC, Barcelona 08916, Spain

[4] Univ Valencia, Hosp Clin, Valencia, Spain

[5] Hosp Univ Cent Asturias, Oviedo, Spain

[6] Hosp Valle De Hebron, Barcelona, Spain

[7] Hosp del Mar, Barcelona, Spain

[8] Hosp Gen Castellon, Castellon de La Plana, Spain

[9] Hosp Univ Marques Valdecilla, Santander, Spain

[10] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[11] Hosp Univ 12 Octubre, Madrid, Spain

[12] Hosp Basurto, Bilbao, Spain

[13] Hosp Gen Univ Valencia, Valencia, Spain

[14] Hosp Univ Virgen Macarena, Seville, Spain

[15] Hosp Clin Univ, Fdn Publ Galega Med Xenom, Santiago, Spain

[16] Hosp Univ & Politecn La Fe, Valencia, Spain

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 11期

关键词：

Myelodysplastic syndromes; cytogenetics; FISH; chromosome; 17; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC SCORING SYSTEM; PREDICTING SURVIVAL; DELETION; MDS; KARYOTYPE;

D O I：

10.3109/10428194.2015.1028053

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected - 17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 0.9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype. We recommend using FISH of 17p13 in young patients with a normal karyotype or non-informative cytogenetics, and always in isolated del(17p)

引用

页码：3183 / 3188

页数：6

共 50 条

[21] The Usefulness of Fluorescence In Situ Hybridization in the Diagnosis of Myelodysplastic Syndromes
Kowk, B.
Loghavi, S.
Hussong, J.
Alsabeh, R.
LABORATORY INVESTIGATION, 2010, 90 : 308A - 308A
[22] The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
McGraw, K. L.
Zhang, L. M.
Rollison, D. E.
Basiorka, A. A.
Fulp, W.
Rawal, B.
Jerez, A.
Billingsley, D. L.
Lin, H-Y
Kurtin, S. E.
Yoder, S.
Zhang, Y.
Guinta, K.
Mallo, M.
Sole, F.
Calasanz, M. J.
Cervera, J.
Such, E.
Gonzalez, T.
Nevill, T. J.
Haferlach, T.
Smith, A. E.
Kulasekararaj, A.
Mufti, G.
Karsan, A.
Maciejewski, J. P.
Sokol, L.
Epling-Burnette, P. K.
Wei, S.
List, A. F.
BLOOD CANCER JOURNAL, 2015, 5 : e291 - e291
[23] The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
K L McGraw
L M Zhang
D E Rollison
A A Basiorka
W Fulp
B Rawal
A Jerez
D L Billingsley
H-Y Lin
S E Kurtin
S Yoder
Y Zhang
K Guinta
M Mallo
F Solé
M J Calasanz
J Cervera
E Such
T González
T J Nevill
T Haferlach
A E Smith
A Kulasekararaj
G Mufti
A Karsan
J P Maciejewski
L Sokol
P K Epling-Burnette
S Wei
A F List
Blood Cancer Journal, 2015, 5 : e291 - e291
[24] Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization for detecting chromosome abnormalities in myelodysplastic syndromes A retrospective study
Ai, Xiaofei
Li, Bing
Xu, Zefeng
Liu, Jinqin
Qin, Tiejun
Li, Qinghua
Xiao, Zhijian
MEDICINE, 2021, 100 (18) : E25768
[25] Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
Dutta, Sayantanee
Moritz, Jennifer
Pregartner, Gudrun
Thallinger, Gerhard G.
Brandstaetter, Ilona
Lind, Karin
Rezania, Simin
Lyssy, Freya
Reinisch, Andreas
Zebisch, Armin
Berghold, Andrea
Woelfler, Albert
Sill, Heinz
ANNALS OF HEMATOLOGY, 2022, 101 (04) : 837 - 846
[26] Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
Sayantanee Dutta
Jennifer Moritz
Gudrun Pregartner
Gerhard G. Thallinger
Ilona Brandstätter
Karin Lind
Simin Rezania
Freya Lyssy
Andreas Reinisch
Armin Zebisch
Andrea Berghold
Albert Wölfler
Heinz Sill
Annals of Hematology, 2022, 101 : 837 - 846
[27] CHROMOSOME-17 ABNORMALITIES AND TP53 MUTATIONS IN ADULT SOFT-TISSUE SARCOMAS
LATRES, E
DROBNJAK, M
POLLACK, D
OLIVA, MR
RAMOS, M
KARPEH, M
WOODRUFF, JM
CORDONCARDO, C
AMERICAN JOURNAL OF PATHOLOGY, 1994, 145 (02): : 345 - 355
[28] Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia
Tavor, Sigal
Rothman, Rachel
Golan, Tamar
Voskoboinik, Nadia
Katz, Ben-Zion
Sarid, Nadav
Shomrat, Ruth
Orr-Urtreger, Avi
Naparstek, Elizabeth
LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 642 - 647
[29] Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies
Anderson, K
Arvidsson, I
Jacobsson, J
Hast, R
CANCER GENETICS AND CYTOGENETICS, 2002, 136 (02) : 101 - 107
[30] Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization
Sessarego, M
Fugazza, G
Gobbi, M
Bruzzone, R
Bisio, R
Ghio, R
Patrone, F
CANCER GENETICS AND CYTOGENETICS, 1998, 106 (02) : 110 - 115

← 1 2 3 4 5 →